Spots Global Cancer Trial Database for ribociclib
Every month we try and update this database with for ribociclib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | NCT03114527 | Soft Tissue Sar... | Ribociclib Everolimus | 18 Years - | Fox Chase Cancer Center | |
| Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | NCT04852081 | Breast Cancer S... | Palbociclib Ribociclib Abemaciclib Letrozole Anastrozole Tamoxifen Fulvestrant Exemestane Alpelisib | 18 Years - | Blokhin's Russian Cancer Research Center | |
| A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | NCT03355794 | Diffuse Intrins... Malignant Gliom... High Grade Glio... Bithalamic High... Brainstem Gliom... Glioblastoma Anaplastic Astr... | ribociclib Everolimus | 12 Months - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole | NCT05163106 | Breast Cancer HER2-negative B... ER-positive Bre... Locally Advance... Luminal A Breas... Luminal B Breas... | Letrozole 2.5mg... Goserelin | 18 Years - | University Hospital, Akershus | |
| A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | NCT06188520 | ER+ HER2- Advan... High-grade Sero... | AZD8421 Camizestrant Ribociclib Palbociclib Abemaciclib | 18 Years - | AstraZeneca | |
| Ribociclib and Spartalizumab in R/M HNSCC | NCT04213404 | Head and Neck S... | Ribociclib Spartalizumab | 20 Years - 70 Years | National Taiwan University Hospital | |
| Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression | NCT02555189 | Castration-Resi... Metastatic Pros... Prostate Carcin... Stage IV Prosta... | Enzalutamide Ribociclib Laboratory Biom... Pharmacological... Biospecimen Col... Biopsy Echocardiograph... Multigated Acqu... Bone Scan Computed Tomogr... Magnetic Resona... | 18 Years - | Thomas Jefferson University | |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | NCT05467891 | Locoregional Re... Hormone Recepto... HER2-negative B... | Ribociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Hoosier Cancer Research Network | |
| A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment | NCT06311383 | Breast Cancer | First-line Ribo... First-line endo... First-line chem... | 18 Years - | Novartis | |
| Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer | NCT05296746 | Breast Cancer S... | Ribociclib (neo... Chemotherapy (a... Ribociclib (adj... | 18 Years - | SOLTI Breast Cancer Research Group | |
| Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer | NCT05296746 | Breast Cancer S... | Ribociclib (neo... Chemotherapy (a... Ribociclib (adj... | 18 Years - | SOLTI Breast Cancer Research Group | |
| Next Generation Personalized Neuroblastoma Therapy | NCT02780128 | Neuroblastoma Cancer | Biopsy Next Generation... Tumor Scans Bone marrow Tes... Physical Exam Eye Exam Labs Pregnancy Test Interviews ECG Echocardiogram Ribociclib Ceritinib | 1 Year - 21 Years | Children's Hospital of Philadelphia | |
| A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma | NCT03008408 | Recurrent Endom... Recurrent Endom... Refractory Endo... Refractory Endo... Stage III Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Uterin... Stage IVA Uteri... Stage IVB Uteri... | Everolimus Letrozole Ribociclib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| Ribociclib and Spartalizumab in R/M HNSCC | NCT04213404 | Head and Neck S... | Ribociclib Spartalizumab | 20 Years - 70 Years | National Taiwan University Hospital | |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | NCT03333343 | EGFR-mutant Non... | EGF816 trametinib ribociclib LXH254 INC280 gefitinib | 18 Years - | Novartis | |
| Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | NCT03294694 | Metastatic Horm... HER2-Negative B... Metastatic Epit... | Ribociclib PDR001 Fulvestrant | 18 Years - | Dana-Farber Cancer Institute | |
| Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib | NCT05625087 | Breast Cancer S... | Alpelisib Ribociclib | 18 Years - | UNICANCER | |
| A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer | NCT03956654 | Breast Cancer | Ribociclib | 70 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients | NCT05452213 | Breast Cancer Breast Neoplasm... Breast Neoplasm... Breast Cancer F... HER2-negative B... Hormone Recepto... Advanced Breast... | Ribociclib | 18 Years - | Institut fuer Frauengesundheit | |
| Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC | NCT03905343 | Breast Cancer | Ribociclib Mono-chemothera... Endocrine-Thera... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Study of Ribociclib and Everolimus in HGG and DIPG | NCT05843253 | High Grade Glio... Diffuse Intrins... Anaplastic Astr... Glioblastoma Glioblastoma Mu... Diffuse Midline... Metastatic Brai... WHO Grade III G... WHO Grade IV Gl... | Ribociclib Everolimus | 12 Months - 39 Years | Nationwide Children's Hospital | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | NCT04802759 | Inoperable, Loc... | Giredestrant Abemaciclib Ipatasertib Inavolisib Ribociclib Everolimus Samuraciclib PH FDC SC Palbociclib Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer | NCT06075758 | Breast Cancer | ribociclib | 18 Years - 100 Years | Novartis | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| A Deep Learning Method to Evaluate QT on Ribociclib | NCT05623397 | Breast Cancer Ribociclib | Acquisition of ... | 18 Years - | CMC Ambroise Paré | |
| Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression | NCT02555189 | Castration-Resi... Metastatic Pros... Prostate Carcin... Stage IV Prosta... | Enzalutamide Ribociclib Laboratory Biom... Pharmacological... Biospecimen Col... Biopsy Echocardiograph... Multigated Acqu... Bone Scan Computed Tomogr... Magnetic Resona... | 18 Years - | Thomas Jefferson University | |
| Impact of Ribociclib on Head and Neck Squamous Cell Cancer | NCT03179956 | Squamous Cell C... | Ribociclib | 18 Years - | Fox Chase Cancer Center | |
| Ribociclib (LEE011) Rollover Study for Continued Access | NCT02934568 | Continued Acces... | LEE011 | - 80 Years | Novartis | |
| Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients | NCT02933736 | Glioblastoma Mu... Meningioma | Ribociclib | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | NCT06409390 | Metastatic Brea... | Taxotere Cytoxan Trastuzumab der... Sacituzumab gov... Xeloda Fulvestrant Ribociclib Abemaciclib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Ribociclib (LEE011) Rollover Study for Continued Access | NCT02934568 | Continued Acces... | LEE011 | - 80 Years | Novartis | |
| Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | NCT04055493 | Breast Cancer F... | Ribociclib 200M... | 18 Years - | West German Study Group | |
| Ribociclib and Spartalizumab in R/M HNSCC | NCT04213404 | Head and Neck S... | Ribociclib Spartalizumab | 20 Years - 70 Years | National Taiwan University Hospital | |
| A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer | NCT03956654 | Breast Cancer | Ribociclib | 70 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | NCT02734615 | Advanced or Met... | LSZ102 LEE011 BYL719 | 18 Years - | Novartis | |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | NCT02974725 | Non-Small Cell ... Melanoma | LXH254 LTT462 Trametinib Ribociclib | 18 Years - | Novartis | |
| Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients | NCT05452213 | Breast Cancer Breast Neoplasm... Breast Neoplasm... Breast Cancer F... HER2-negative B... Hormone Recepto... Advanced Breast... | Ribociclib | 18 Years - | Institut fuer Frauengesundheit | |
| Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | NCT02703571 | Solid Tumors fo... Pancreatic Canc... Colorectal Canc... | ribociclib Trametinib | 18 Years - | Novartis | |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin | NCT02420691 | Advanced Digest... Duodenal Neuroe... Functional Panc... Gastric Neuroen... Intermediate Gr... Low Grade Lung ... Nonfunctional P... Thymus Neoplasm | Laboratory Biom... Pharmacological... Ribociclib | 18 Years - | M.D. Anderson Cancer Center | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | NCT02571829 | Liposarcoma Soft Tissue Sar... | ribociclib | 18 Years - | Hadassah Medical Organization | |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | NCT03009201 | Advanced Soft T... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Angi... Metastatic Epit... Metastatic Fibr... Metastatic Lipo... Metastatic Mali... Metastatic Myxo... Metastatic Soft... Metastatic Syno... Metastatic Undi... Myxofibrosarcom... Pleomorphic Rha... Stage III Soft ... Stage IV Soft T... Undifferentiate... Unresectable Le... Unresectable Li... Unresectable Ma... Unresectable So... Unresectable Sy... Unresectable Un... | Doxorubicin Hyd... Laboratory Biom... Pharmacological... Ribociclib | 12 Years - | OHSU Knight Cancer Institute | |
| Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. | NCT03283384 | Breast Neoplasm... | Letrozole Chemotherapy Ribociclib plus... | 18 Years - | Borstkanker Onderzoek Groep | |
| Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors | NCT03237390 | Advanced Malign... Metastatic Mali... | Gemcitabine Hyd... Laboratory Biom... Pharmacological... Ribociclib | 18 Years - | Mayo Clinic | |
| Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors | NCT03237390 | Advanced Malign... Metastatic Mali... | Gemcitabine Hyd... Laboratory Biom... Pharmacological... Ribociclib | 18 Years - | Mayo Clinic | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | NCT03424005 | Breast Cancer | Capecitabine Atezolizumab Ipatasertib SGN-LIV1A Bevacizumab Chemotherapy (G... Selicrelumab Tocilizumab Nab-Paclitaxel Sacituzumab Gov... Abemaciclib Fulvestrant Ribociclib Inavolisib Inavolisib (9 m... Inavolisib (6 m... Trastuzumab Der... | 18 Years - | Hoffmann-La Roche | |
| Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC | NCT03905343 | Breast Cancer | Ribociclib Mono-chemothera... Endocrine-Thera... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection | NCT03834740 | Glioblastoma Mu... Glioma of Brain | Ribociclib Everolimus | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | NCT03096912 | Liposarcomas, D... Liposarcoma - W... Liposarcoma; Mi... Soft-Tissue Sar... | Ribociclib | 18 Years - | Assaf-Harofeh Medical Center | |
| Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | NCT06380751 | Advanced Breast... | Saruparib (AZD5... Camizestrant Abemaciclib Ribociclib Palbociclib Fulvestrant Letrozole Anastrozole Exemestane | 18 Years - 130 Years | AstraZeneca | |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | NCT03333343 | EGFR-mutant Non... | EGF816 trametinib ribociclib LXH254 INC280 gefitinib | 18 Years - | Novartis | |
| Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole | NCT05163106 | Breast Cancer HER2-negative B... ER-positive Bre... Locally Advance... Luminal A Breas... Luminal B Breas... | Letrozole 2.5mg... Goserelin | 18 Years - | University Hospital, Akershus | |
| Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer | NCT03555877 | Breast Cancer M... | Ribociclib Anastrozole Letrozole Exemestane Fulvestrant | 18 Years - | German Breast Group | |
| Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | NCT04055493 | Breast Cancer F... | Ribociclib 200M... | 18 Years - | West German Study Group | |
| Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer | NCT05563220 | Breast Cancer Metastatic Brea... | Elacestrant Alpelisib Everolimus Ribociclib Palbociclib Capivasertib Abemaciclib | 18 Years - | Stemline Therapeutics, Inc. | |
| Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | NCT02657928 | Estrogen Recept... Postmenopausal Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... | Laboratory Biom... Letrozole Ribociclib | 18 Years - | Mayo Clinic | |
| A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection | NCT03834740 | Glioblastoma Mu... Glioma of Brain | Ribociclib Everolimus | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | NCT05759949 | PIK3CA Mutation Solid Tumor, Ad... HER2-negative B... Breast Cancer Metastatic Brea... Advanced Breast... Unresectable So... Hormone Recepto... | RLY-5836 Fulvestrant Palbociclib Ribociclib Abemaciclib | 18 Years - | Relay Therapeutics, Inc. | |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | NCT06065748 | Estrogen Recept... | Giredestrant Fulvestrant Abemaciclib Palbociclib Ribociclib LHRH Agonist FoundationOne L... | 18 Years - | Hoffmann-La Roche | |
| LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC | NCT02494921 | Prostate Cancer | Docetaxel-PNP Ribociclib Prednisone Filgrastim | 18 Years - | University of California, San Francisco | |
| Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. | NCT03671330 | Breast Cancer | Ribociclib Plac... Ribociclib NSAI: Letrozole... Letrozole Goserelin | 18 Years - 60 Years | Novartis | |
| Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | NCT02703571 | Solid Tumors fo... Pancreatic Canc... Colorectal Canc... | ribociclib Trametinib | 18 Years - | Novartis | |
| An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. | NCT02657343 | Breast Cancer | Ribociclib T-DM1 Trastuzumab Fulvestrant | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | NCT02974725 | Non-Small Cell ... Melanoma | LXH254 LTT462 Trametinib Ribociclib | 18 Years - | Novartis | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | NCT03424005 | Breast Cancer | Capecitabine Atezolizumab Ipatasertib SGN-LIV1A Bevacizumab Chemotherapy (G... Selicrelumab Tocilizumab Nab-Paclitaxel Sacituzumab Gov... Abemaciclib Fulvestrant Ribociclib Inavolisib Inavolisib (9 m... Inavolisib (6 m... Trastuzumab Der... | 18 Years - | Hoffmann-La Roche | |
| A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | NCT02607124 | High Grade Glio... Diffuse Intrins... Bithalamic High... | Ribociclib | 12 Months - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression | NCT02555189 | Castration-Resi... Metastatic Pros... Prostate Carcin... Stage IV Prosta... | Enzalutamide Ribociclib Laboratory Biom... Pharmacological... Biospecimen Col... Biopsy Echocardiograph... Multigated Acqu... Bone Scan Computed Tomogr... Magnetic Resona... | 18 Years - | Thomas Jefferson University | |
| Phase 1b Combo w/ Ribociclib and Alpelisib | NCT05508906 | Metastatic Brea... Advanced Breast... HR-positive Bre... HER2-negative B... | OP-1250 Ribociclib Alpelisib | 18 Years - | Olema Pharmaceuticals, Inc. | |
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | NCT06377852 | Metastatic Brea... | Palbociclib Ribociclib | 65 Years - | American Society of Clinical Oncology | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | NCT04802759 | Inoperable, Loc... | Giredestrant Abemaciclib Ipatasertib Inavolisib Ribociclib Everolimus Samuraciclib PH FDC SC Palbociclib Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | NCT03009201 | Advanced Soft T... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Angi... Metastatic Epit... Metastatic Fibr... Metastatic Lipo... Metastatic Mali... Metastatic Myxo... Metastatic Soft... Metastatic Syno... Metastatic Undi... Myxofibrosarcom... Pleomorphic Rha... Stage III Soft ... Stage IV Soft T... Undifferentiate... Unresectable Le... Unresectable Li... Unresectable Ma... Unresectable So... Unresectable Sy... Unresectable Un... | Doxorubicin Hyd... Laboratory Biom... Pharmacological... Ribociclib | 12 Years - | OHSU Knight Cancer Institute | |
| Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer | NCT03822468 | Breast Cancer | Ribociclib Anastrozole Letrozole Goserelin | 18 Years - | Novartis | |
| Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | NCT06409390 | Metastatic Brea... | Taxotere Cytoxan Trastuzumab der... Sacituzumab gov... Xeloda Fulvestrant Ribociclib Abemaciclib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | NCT04852081 | Breast Cancer S... | Palbociclib Ribociclib Abemaciclib Letrozole Anastrozole Tamoxifen Fulvestrant Exemestane Alpelisib | 18 Years - | Blokhin's Russian Cancer Research Center | |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | NCT02586675 | Breast Cancer Breast Cancer -... Breast Cancer -... | Tamoxifen Ribociclib Goserelin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | NCT02586675 | Breast Cancer Breast Cancer -... Breast Cancer -... | Tamoxifen Ribociclib Goserelin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
